BioSpace News Archive

Bold Therapeutics, a clinical-stage biopharmaceutical company developing first-in-class oncology therapeutics, announced positive interim results in advanced gastric and biliary tract cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Novocure (NASDAQ: NVCR) today is presenting positive results from the phase 3 LUNAR clinical trial evaluating the use of Tumor Treating Fields (TTFields) therapy together with standard therapies for the treatment of non-small cell lung cancer (NSCLC) at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Agilent Technologies Inc. announced the release of the enhanced xCELLigence RTCA Software Pro Version 2.8, an integrated software package for running and analyzing real-time cell analysis data.

Starton Therapeutics, Inc. and Healthwell Acquisition Corp. today announced that the leadership of Starton and Healthwell will present at the Jefferies Healthcare Conference on June 8th at 11:00 a.m. ET.

ABVC BioPharma, Inc. announced that BioKey, a wholly-owned subsidiary of the Company based in Fremont, California, signed a collaborative agreement with MerDury BioPharma on June 1st, 2023 to co-develop new drug products leveraging MerDury’s StackDoseTM platform technology.

A review of more than 245,000 doses of mRNA COVID-19 vaccines given to young children found no indications of serious side effects.

Natera, Inc. today announced that members of its management team will present at the Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June 13 at 5:40 pm ET | 2:40 pm PT in Dana Point, CA.

Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, is pleased to announce the appointment of Michael Gray as both Chief Operating Officer (COO) and Chief Financial Officer (CFO).

Astria Therapeutics, Inc. granted stock options to purchase 20,000 shares of Astria’s common stock on June 1, 2023 under Astria’s 2022 Inducement Stock Incentive Plan.

Ensysce Biosciences, Inc. today announced two upcoming presentations in June. Chief Medical Officer, Dr. Bill Schmidt, will present in The College on Problems of Drug Dependence (CPDD) 85th Annual Scientific Meeting in Denver, CO, on June 17-21, 2023.